DRG uses cookies to improve your experience on this website. Some of the cookies we use are essential for parts of the website to operate. Please be aware that if you continue without changing your cookie settings, you consent to this. For more information on our use of cookies, please review our cookie policy.

Real World Brand Tracker

Track your Immune Checkpoint Inhibitor brand share with real time US claims brand data.

  • Understand shifting market dynamics and impact of events on Immune Checkpoint Inhibitor (ICI) use across oncology indications
  • Track payer metrics (including total claim amount submitted and total claim paid) over time
  • Utilize claims data to help inform clinical trial strategy
  • Uncover pockets of opportunity for improved Immune Checkpoint Inhibitor penetration
  • Recognize where and why Immune Checkpoint Inhibitor brands are performing poorly

Yervoy | Keytruda | Opdivo | Tecentriq | Bavencio | Imfinzi 

| Libtayo

Indications covered in Real World Brand Tracker include Malignant Melanoma, Lung Cancer, Renal Cell Carcinoma, Hodgkin’s Lymphoma, Bladder Cancer, Head and Neck Cancer, Merkel Cell Carcinoma, Colorectal Cancer, Hepatocellular Carcinoma and Gastric Cancer. We commit to cover every new Immune Checkpoint Inhibitor following approval and for every new indication for current Immune Checkpoint Inhibitors.

Learn more